Tumor Board: What It Is, How It Works, and Why It Can Change Your Treatment

If you have recently received an oncology diagnosis or if a loved one is going through such a situation, you may have heard the term “Tumor Board” or “Oncology Commission” without knowing exactly what it means. What goes on behind these closed doors? Who makes the decisions about your treatment? And, most importantly: how can you be sure that the decision made is the best for your specific situation? This guide explains, in your own words, what the Tumor Board is, why it is essential in modern oncology, and how you can benefit from it to the fullest.

What is a Tumor Board? Definition in Plain English

A Tumor Board — also known in Romania as the Oncological Commission or the Multidisciplinary Oncology Committee — is a formal meeting of a team of specialist doctors from several medical disciplines. They meet periodically to jointly analyze the case of a cancer patient and make a collective decision on the best treatment plan.

In short: instead of a single doctor deciding on your treatment, an entire team of experts — each with their own perspective — analyzes your medical record from all possible angles and comes up with a consensus recommendation.

This practice is considered the gold standard in modern oncology . Leading international guidelines — both ESMO (European Society for Medical Oncology) and NCCN (National Comprehensive Cancer Network) — strongly recommend that all complex oncological cases be discussed in a mandatory Tumor Board.

Who is part of a Tumor Board?

The composition of the team varies depending on the type of cancer being discussed, but a complete team usually includes:

Medical oncologist – coordinates systemic treatments (chemotherapy, immunotherapy, targeted therapies)
The oncologist surgeon – evaluates whether the tumor can be operated on and under what conditions
The radiation therapist – analyzes whether radiotherapy is indicated and at what point in the treatment
Radiologist – interprets medical imaging (CT, MRI, PET-CT) and explains the extent of the disease to the team
The pathologist – presents the biopsy results, tumor grading and immunohistochemical (IHC) profile
Geneticist – when there is suspicion of inherited genetic mutations (e.g. BRCA1/2 in breast cancer)
Oncologist psychologist – in advanced centers, to address the emotional aspects of the therapeutic decision

This diversity of specialists is precisely the strength of a Tumor Board: no specialist sees the entire clinical picture alone, but together they build the complete picture of your medical situation.

How Does a Tumor Board Meeting Proceed?

A typical session is usually held once a week or every two weeks , in hospitals and oncology centers with adequate infrastructure. Here’s what it looks like, step by step:

Case presentation – A treating physician briefly presents the patient’s history, diagnosis, and investigation results.
Imaging analysis – The radiologist presents the CT or MRI images on the screen, indicating the size, location, and anatomical relationships of the tumor.
Presentation of the histopathology report – The pathologist details the histological type, tumor grading, TNM classification, and IHC profile.
Multidisciplinary discussion – Each specialist expresses his opinion from his perspective: the surgeon evaluates resectability, the radiotherapist calculates the irradiation fields, the oncologist proposes the systemic protocol.
Therapeutic consensus – The team reaches a unanimous or majority recommendation, documented in the patient’s chart in the form of a multidisciplinary therapeutic plan .

Is the patient present at this meeting? Usually not. The medical file is discussed in the patient’s absence, and the treating physician subsequently communicates the decision and explains it to the patient and family.

What Specific Therapeutic Decisions Are Made in the Tumor Board?

A Tumor Board’s decisions are not simple — they integrate dozens of variables simultaneously. The team may decide:

Order of treatments : Is surgery done first, or is chemotherapy done first to shrink the tumor ( neoadjuvant chemotherapy )?
Type of surgery : Conservative or radical intervention? Is the tumor resectable?
Chemotherapy protocol : What combination of drugs, in what doses and for what duration?
Radiotherapy indication : Adjuvant after surgery or concurrent with chemotherapy?
Targeted therapies or immunotherapy : Based on genetic markers and IHC, is the patient a candidate for monoclonal antibodies, immune checkpoint inhibitors, or mutation-specific therapies (e.g., EGFR, ALK, BRAF)?
Extended genetic testing (NGS — Next Generation Sequencing): Is it necessary to request a complete tumor genetic profile to identify new therapeutic targets?

Studies published in the specialized oncology literature show that discussing cases in the Tumor Board modifies the initial treatment plan in 20–30% of cases — which means that for 1 in 4 patients, the oncology committee completely changes the direction of therapy compared to what a single specialist would have decided.

Why Does the Tumor Board Matter to You as a Patient?

Many patients are unaware that they have the right to request that their case be presented to a Tumor Board or to request a second opinion. Here’s why this is essential:

Reduces decision errors : A single doctor, no matter how good, may not be aware of the latest clinical trials for a rare type of cancer. A multidisciplinary team is much better at covering the entire medical literature.
Personalize the treatment : The decision is not based on a generic protocol, but on the specific data of your file — histological type, TNM stage, IHC profile, your general condition and your preferences as a patient.
Provides therapeutic coherence : All specialties involved work with the same plan, eliminating the risk of contradictory treatments.
International validation : Oncology centers of excellence in Europe and the USA operate exclusively based on Tumor Board decisions.

How Do You Prepare for the Oncology Commission? List of Essential Documents

If your treating physician has told you that your case will be discussed in committee, or if you intend to seek a second opinion, your medical record must be complete . An incomplete record may lead to a suboptimal decision or delayed recommendations.

The essential documents for a Tumor Board are:

✅ Histopathology report (biopsy result) with full IHC profile
✅ Digital imaging (CD with CT/MRI/PET-CT images, not just the written report sheet)
✅ Medical discharge letter or letter from the treating physician
✅ Recent blood tests (complete blood count, biochemistry, tumor markers)
✅ Genetic tests , if available (NGS profile, BRCA tests, etc.)
✅ History of previous treatments , if you have already undergone chemotherapy or radiotherapy

Conclusion: Don’t Go to the Tumor Board Without Understanding What’s in Your File

The Tumor Board is the most important moment in your oncology journey — the moment when the therapeutic strategy is decided, which can directly influence your quality of life and prognosis. Don’t let this moment pass without being prepared.

Understand every document in your file. Check for completeness. Ask for a second opinion if you have any doubts. And use all available resources — including digital ones — to ensure you receive the best possible treatment, aligned with international standards.

📂 Do you want to know if your medical file is complete for a Tumor Board evaluation? Upload your documents to Oncoexpertai.com and get a detailed analysis assisted by Artificial Intelligence, which checks the completeness of your file and correlates it with the latest international oncology protocols.

Digital Tumor Board: How Artificial Intelligence Helps Before the Official Commission

One of the biggest hurdles patients face is not knowing how complete their file is or understanding what the data in the file means before they go to the oncology board. The result? Patients who arrive at the Tumor Board with incomplete files, who receive delayed recommendations, or who don’t understand what the medical team has decided for them.

The platform functions as a digital “pre-Tumor Board” , assisted by Artificial Intelligence:

Analyze your medical record and identify which documents are missing or insufficient for a correct oncological decision.
Correlate your IHC profile, TNM stage and histological type with the latest ESMO and NCCN international guidelines, updated in real time.
Generate a structured report that can be presented to your treating physician or Tumor Board team, showing internationally validated therapeutic options for your specific disease profile.
Explain in accessible language every technical term in your file so that you can actively and informedly participate in the conversation with the medical team.

Important : The Oncoexpertai platform does not replace the doctor and does not issue a diagnosis . Its role is to help you understand the file, check its completeness and present yourself to the oncology committee with the homework done — that is, to know what questions to ask, what options exist and what international standards apply to your case.

If you just want a completely free opinion without uploading any medical documents, use one of the 2 orange boxes “Talk to Dr. Onisim” or green “Message to Dr. Onisim”

Disclaimer: The information in this article is for informational and educational purposes only. It does not constitute personalized medical advice and does not replace the consultation of a specialist physician. Any therapeutic decision should be made exclusively after consultation with your medical team.

Bibliografie

Borras JM, Albreht T, Audisio R, Briers E, Casali P, Esperou H, et al. Policy statement on multidisciplinary cancer care. European Journal of Cancer. 2014;50(3):475–480. doi:10.1016/j.ejca.2013.11.012.
Prades J, Remue E, van Hoof E, Borras JM. Is it worth reorganising cancer services on the basis of multidisciplinary teams? A systematic review of the objectives and organisation of multidisciplinary teams and their impact on patient outcomes. Health Policy. 2015;119(4):464–474. doi:10.1016/j.healthpol.2014.09.006.
Lamb BW, Brown KF, Nagpal K, Vincent C, Green JSA, Sevdalis N. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Annals of Surgical Oncology. 2011;18(8):2116–2125. doi:10.1245/s10434-011-1675-6.
Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews. 2016;42:56–72. doi:10.1016/j.ctrv.2015.11.007.
Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ. Tumor boards and the quality of cancer care. Journal of the National Cancer Institute. 2013;105(2):113–121. doi:10.1093/jnci/djs502.
Friedland PL, Bozic B, Dewar J, Kuan R, Meyer C, Phillips M. Impact of multidisciplinary team management in head and neck cancer patients. British Journal of Cancer. 2011;104(8):1246–1248. doi:10.1038/bjc.2011.92.
Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, et al. Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Annals of Oncology. 2012;23(4):853–859. doi:10.1093/annonc/mdr352.
Specchia ML, Frisicale EM, Carini E, Di Pilla A, Cappa D, Barbara A, et al. The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Services Research. 2020;20:73. doi:10.1186/s12913-020-4930-3.
National Cancer Institute. Tumor board review. NCI Dictionary of Cancer Terms. Bethesda: National Cancer Institute. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tumor-board-review
European Society for Medical Oncology. ESMO Clinical Practice Guidelines. Lugano: ESMO. Available from: https://www.esmo.org/guidelines
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Plymouth Meeting: NCCN. Available from: https://www.nccn.org/guidelines
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. 2020;31(11):1491–1505. doi:10.1016/j.annonc.2020.07.014.
Schilsky RL, Michels DL, Kearbey AH, Yu PP, Hudis CA. Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ. Journal of Clinical Oncology. 2014;32(22):2373–2379. doi:10.1200/JCO.2014.56.2124.
Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine. 2019;25(1):44–56. doi:10.1038/s41591-018-0300-7.
Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nature Biomedical Engineering. 2018;2(10):719–731. doi:10.1038/s41551-018-0305-z.

Dr. Onisim Florin Senior Medical Oncologist | Founder of OncoExpertAI

Bibliografie

Onisim Florin

Login